Tasquinimod + cabazitaxel in heavily pre-treated men with mCRPC

Posted on January 23, 2012 by Sitemaster

According to media information from Active Biotech this morning, the company has initiated an early stage, combination therapy trial (the so-called CATCH trial) of their investigational agent tasquinimod + cabazitaxel (Jevtana®) for the treatment of men with heavily pre-treated, metastatic, castration-resistant prostate cancer (mCRPC).

Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: , , , , , | Leave a Comment »

Full results of the AFFIRM trial at GU Oncology meeting next month

Posted on January 9, 2012 by Sitemaster

According to a joint media release from Medivation and Astellas Pharma earlier today, the full results of the Phase III AFFIRM trial — of MDV3100 in men with metastatic castration-resistant prostate cancer (mCRPC) who have received docetaxel chemotherapy — will be presented at the ASCO Genitourinary Oncology meeting on February 2, 2012.

Filed under: Drugs in development, Management, Treatment | Tagged: , , , | Leave a Comment »

Barvarian Nordic starts multi-center, Phase III trial of Prostvac

Posted on November 15, 2011 by Sitemaster

Barvarian Nordic has initiated the expected, randomized, multi-center Phase III trial of Prostvac® in men with asymptomatic and minimally symptomatic, metastatic, castration-resistant prostate cancer (mCRPC).

Filed under: Drugs in development, Management, Treatment | Tagged: , , , | 4 Comments »

New data on cabozantinib (XL184) in men with mCRPC

Posted on November 14, 2011 by Sitemaster

Additional data about the effectiveness and safety of cabozantinib were reported over the past weekend at a meeting in San Francisco.

Filed under: Drugs in development, Management, Treatment, Uncategorized | Tagged: , , , , | Leave a Comment »

MDV3100 shows survival benefit in Phase III AFFIRM trial

Posted on November 3, 2011 by Sitemaster

According to a Reuters report and a media release this morning, Medivation has announced that interim results of the Phase III AFFIRM trial showed a 4.8-month survival benefit for treatment with MDV3100 compared to a placebo in men with metastatic, castration-resistant prostate cancer after treatment with docetaxel-based chemotherapy.

Filed under: Drugs in development, Management, Treatment | Tagged: , , , | 2 Comments »

Two phase III trials planned for cabozantinib in mCRPC

Posted on November 1, 2011 by Sitemaster

Accoring to a Bloomberg Businessweek report and information on the Exelixis corporate web site, the company is planning two multi-center, randomized, Phase III clinical trials of the investigational agent cabozantinib (a.k.a., XL184) in metastatic, castration-resistant prostate cancer (mCRPC):

Filed under: Drugs in development, Management, Treatment | Tagged: , , , , | Leave a Comment »

Potential future agents in the management of mCRPC

Posted on October 31, 2011 by Sitemaster

A new article by Antonarakis and Armstrong in full text on the Medscape web site reviews available information on a wide range of currently investigational agents for the treatment of metastatic, castration-resistant prostate cancer (mCRPC), including

Filed under: Drugs in development, Management, Treatment | Tagged: , , , , | 3 Comments »

Does eribulin mesylate have potential in mCRPC … or not?

Posted on October 3, 2011 by Sitemaster

In May 2010 we reported that a product called eribulin mesylate had been tested (in the USA) in a Phase II clinical trial for its activity in metastatic, castration-resistant prostate cancer (mCRPC) — and that the results were not particularly promising.

Filed under: Drugs in development, Management, Treatment | Tagged: , , , | 3 Comments »

New options after standard hormone therapy has failed

Posted on October 1, 2011 by Sitemaster

We apparently managed to overlook a series of three review and commentary articles published in Oncology in May this year that dealt with the evolving options that have already — or will soon — come available for the treatment of castration-resistant prostate cancer (CRPC).

Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: , , , , | 2 Comments »

FDA fast tracks NDA for Alpharadin in mCRPC

Posted on August 23, 2011 by Sitemaster

According to a media release issued by Bayer HealthCare, the U. S. Food & Drug Administration (FDA) has given the green light to “fast track” review of the company’s new drug application (NDA) for Alpharadin™ (radium-223 chloride) as a treatment for men with metastatic, castration-resistant prostate cancer (mCRPC).

Filed under: Drugs in development, Management, Treatment | Tagged: , , , , | 3 Comments »

Carboplatin + etopside in mCRPC: high toxicity and low efficacy

Posted on July 18, 2011 by Sitemaster

The results of the French Genito-Urinary Tumor Group (GETUG) P01 trial — a Phase II study of carboplatin and etoposide in men with progressive metastatic castration-resistant prostate cancer (mCRPC) — have shown that this form of combination chemotherapy has limited efficacy and an unacceptably high toxicity in men with late stage prostate cancer.

Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: , , , , , | Leave a Comment »

Preliminary data on itraconazole in treatment of mCRPC

Posted on June 4, 2011 by Sitemaster

Preliminary data from a Phase II clinical trial have suggested that the antifungal drug itraconazole, when used at high dose levels, may have clinical benefit in the treatment of metastatic, castration-resistant prostate cancer (mCRPC).

Filed under: Drugs in development, Management, Treatment | Tagged: , , , | 2 Comments »

Results of abiraterone acetate Phase III trial in today’s NEJM

Posted on May 26, 2011 by Sitemaster

According to a media release issued by Centocor Ortho Biotech late yesterday, the final results of the Phase III clinical trial of abiraterone acetate + prednisone vs. prednisone alone in men with metastatic, castration-resistant prostate cancer (mCRPC) have been published in today’s issue of the New England Journal of Medicine.

Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment, Uncategorized | Tagged: , , , | Leave a Comment »

MDV3100 vs. abiratetone acetate: the analysts’ perspectives

Posted on May 19, 2011 by Sitemaster

Some readers may be interested in in reading a commentary by John Carroll on the FierceBiotech web site, where he discusses whether MDV3100 is going to be able to “match up” to abiraterone acetate — always assuming that MDV3100 can also show a survival benefit in men with metastatic, castration-resistant prostate cancer (mCRPC).

Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: , , | 2 Comments »

Final publication of data from the ASCENT-2 clinical trial

Posted on May 6, 2011 by Sitemaster

The final report of the result of the ASCENT-2 trial has been published on line in the Journal of Clinical Oncology. The data from this study have been widely reported in the past.

Filed under: Drugs in development, Management, Treatment | Tagged: , , , , , , | Leave a Comment »

« Previous Page — Next Page »
Follow

Get every new post delivered to your Inbox.

Join 325 other followers